Key result
Endothelial CYP2J2 overexpression maintained blood-retinal barrier integrity after ischemia-reperfusion injury and protected against retinal ganglion cell loss via METTL3-mediated ANXA1 upregulation.
Why the study?
Blood-retinal barrier breakdown causes multiple ocular diseases, with increased vascular permeability contributing to vasogenic edema and vision loss.
Does endothelial CYP2J2 overexpression protect against blood-retinal barrier breakdown following ischemia-reperfusion injury?
Does endothelial CYP2J2 overexpression protect against blood-retinal barrier breakdown following ischemia-reperfusion injury?
The CYP2J2-METTL3-ANXA1 pathway is a potential therapeutic target for restoring blood-retinal barrier integrity in ocular diseases.
Offers hypothesis-generating evidence for endothelial CYP2J2 in retinal ischemia; leaves open clinical translation and therapeutic testing.
Blood–retinal barrier (BRB) breakdown is responsible for multiple ocular diseases, such as diabetic retinopathy, age‐related macular degeneration, and retinal vascular occlusive diseases. Increased vascular permeability contributes to vasogenic edema and tissue damage, with consequent adverse effects on vision. Herein, we found that endothelial CYP2J2 overexpression maintained BRB integrity after ischemia–reperfusion injury and consequently protected against retinal ganglion cell loss. Oxidative stress repressed endothelial ANXA1 expression in vivo and in vitro. CYP2J2 upregulated methyltransferase‐like 3 (METTL3) expression and hence promoted ANXA1 translation via ANXA1 m 6 A modification in endothelium under oxidative stress. CYP2J2 maintained the distribution of endothelial tight junctions and adherens junctions in an ANXA1‐dependent manner. Endothelial ANXA1 plays an indispensable role in vascular homeostasis and stabilization during development. Endothelial ANXA1 deletion disrupted retinal vascular perfusion as well as BRB integrity. CYP2J2 metabolites restored BRB integrity in the presence of ANXA1. Our findings identified the CYP2J2–METTL3–ANXA1 pathway as a potential therapeutic target for relieving BRB impairments.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2022) studied Blood-retinal barrier breakdown. Endothelial CYP2J2 overexpression was evaluated on Blood-retinal barrier integrity. Endothelial CYP2J2 overexpression maintained blood-retinal barrier integrity after ischemia-reperfusion injury and protected against retinal ganglion cell loss via METTL3-mediated ANXA1 upregulation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: